124 related articles for article (PubMed ID: 32298597)
1.
Trujillo-Paolillo A; Salinas-Souza C; Dias-Oliveira I; Petrilli AS; Toledo SRC
J Adolesc Young Adult Oncol; 2020 Dec; 9(6):621-627. PubMed ID: 32298597
[No Abstract] [Full Text] [Related]
2. CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
Trujillo-Paolillo A; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia Filho RJ; de Oliveira R; de Toledo SRC
Oncotarget; 2017 Jun; 8(24):38530-38540. PubMed ID: 28404946
[TBL] [Abstract][Full Text] [Related]
3. Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.
Wang K; Zhao J; He M; Fowdur M; Jiang T; Luo S
Tumour Biol; 2016 Jan; 37(1):1105-12. PubMed ID: 26276359
[TBL] [Abstract][Full Text] [Related]
4. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
[TBL] [Abstract][Full Text] [Related]
6. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
7. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
[TBL] [Abstract][Full Text] [Related]
9. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
Pharmacogenet Genomics; 2014 Oct; 24(10):514-21. PubMed ID: 25098908
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 10 gene -1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population.
Cui Y; Zhu JJ; Ma CB; Cui K; Wang F; Ni SH; Zhang ZY
Tumour Biol; 2016 Apr; 37(4):4517-22. PubMed ID: 26503210
[TBL] [Abstract][Full Text] [Related]
13. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
[TBL] [Abstract][Full Text] [Related]
14. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
15. Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study.
Chen YY
Medicine (Baltimore); 2017 Mar; 96(9):e5993. PubMed ID: 28248857
[TBL] [Abstract][Full Text] [Related]
16. [Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231)].
Cui GL; Ding H; Xu YJ; Chen C; Wang DW
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jun; 40(6):477-81. PubMed ID: 22943641
[TBL] [Abstract][Full Text] [Related]
17. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
18. Effects of
Muñoz A; López-Samanes Á; Aguilar-Navarro M; Varillas-Delgado D; Rivilla-García J; Moreno-Pérez V; Del Coso J
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32823594
[TBL] [Abstract][Full Text] [Related]
19. Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.
Goričar K; Kovač V; Jazbec J; Zakotnik B; Lamovec J; Dolžan V
OMICS; 2015 Mar; 19(3):180-5. PubMed ID: 25748439
[TBL] [Abstract][Full Text] [Related]
20. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
